Itraconazole: pharmacologic studies in animals and humans

Area of Science:

• Pharmacology
• Mycology
• Endocrinology

Background:

• Itraconazole is an orally active antifungal triazole.
• Previous antifungals like ketoconazole have shown potential for adverse effects.
• Understanding itraconazole's safety and efficacy profile is crucial for clinical use.

Purpose of the Study:

• To evaluate the pharmacologic properties of itraconazole.
• To compare itraconazole's safety and pharmacokinetic profile with ketoconazole.
• To assess itraconazole's potential for adverse effects and therapeutic spectrum.

Main Methods:

• Pharmacologic studies were conducted in human and animal models (dogs, rats).
• Toxicologic assessments were performed at doses up to 40 mg/kg.
• Endocrinologic and pharmacokinetic studies were utilized to assess steroidogenesis and drug disposition.

Main Results:

• No significant toxic effects were observed in dogs and rats at doses up to 40 mg/kg.
• Itraconazole did not significantly impact human testicular and adrenal steroidogenesis, unlike ketoconazole.
• Itraconazole demonstrated high tissue affinity and a longer half-life compared to ketoconazole.

Conclusions:

• Itraconazole exhibits a broader antifungal spectrum than ketoconazole.
• Itraconazole presents a lower potential for adverse effects compared to ketoconazole.
• The favorable pharmacologic profile of itraconazole supports its clinical utility.